Saframycin A

CAS No. 66082-27-7

Saframycin A ( NSC 325663 )

Catalog No. M15514 CAS No. 66082-27-7

A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Saframycin A
  • Note
    Research use only, not for human use.
  • Brief Description
    A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.
  • Description
    A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro; shows potent antiproliferative effects in leukemia- and tumor-derived cells; induces nuclear translocation of GAPDH in cancer cells.
  • Synonyms
    NSC 325663
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    DNA/RNA Synthesis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    66082-27-7
  • Formula Weight
    562.58
  • Molecular Formula
    C29H30N4O8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC1=C(C(C2=C(C1=O)[C@@H](N3[C@H]([C@H]4N([C@@H]([C@@H]3C#N)CC5=C4C(C(OC)=C(C5=O)C)=O)C)C2)CNC(C(C)=O)=O)=O)C
  • Chemical Name
    N-[[(6S,7R,9R,14aS,15R)-7-Cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxopropanamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Xing C, et al. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5862-6.
2. Ishiguro K, et al. Biochemistry. 1978 Jun 27;17(13):2545-50.
3. Spencer JR, et al. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8.
molnova catalog
related products
  • Helicid

    Helicid is a medicine available in a number of countries worldwide.

  • Beaucage reagent

    A potent DNA cleavage agent.

  • CCG-203971

    CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.